Medicare Patients With MS Face Higher Out-of-Pocket Rx Costs
Projected cumulative out-of-pocket spending for disease-modifying therapies for 2019 was $6,894
THURSDAY, Feb. 14, 2019 (Pharmacist's Briefing) -- Medicare patients with multiple sclerosis (MS) face increasing out-of-pocket costs for disease-modifying therapies, according to a study published in the February issue of Health Affairs.
Daniel M. Hartung, Pharm.D., M.P.H., from Oregon State University/Oregon Health and Science University in Portland, and colleagues used enrollment-weighted Prescription Drug Plan Formulary files (2007 to 2016) to assess changes in pharmacy benefit coverage and cost-sharing amounts for MS disease-modifying therapies in the Medicare Part D program.
The researchers found that the rate of prior authorization use increased from 61 to 66 percent of plans to 84 to 90 percent. There was a decline from 39 to 17 percent in the share of plans with at least one therapy available without limitations. For 2019, the projected cumulative out-of-pocket spending was $6,894. Generic glatiramer acetate was the therapy with the highest out-of-pocket spending.
"Policy makers need to consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for people with MS," the authors write.